No Data
No Data
WuXi XDC Cayman's (HKG:2268) Solid Profits Have Weak Fundamentals
WUXI XDC: Annual Report 2024
WuXi AppTec: Net Profit Boosted by Partial Sale of WuXi XDC Cayman Stake >603259.SH
Guotou Securities: The investment and financing environment for Innovative Drugs is rebounding, CXO Orders and performance improvements are expected.
Global investment and financing in Innovative Drugs continues to improve, and a recovery in R&D demand is anticipated; new Orders are recovering in a timely manner, and there is optimism for improved CXO performance in 2025.
We Think WuXi XDC Cayman (HKG:2268) Can Stay On Top Of Its Debt
Trending Industry Today: SKB BIO-B Leads Losses In Biotechnology Stocks